143 related articles for article (PubMed ID: 17023413)
21. Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor.
Farzan M; Schnitzler CE; Vasilieva N; Leung D; Kuhn J; Gerard C; Gerard NP; Choe H
J Exp Med; 2001 May; 193(9):1059-66. PubMed ID: 11342590
[TBL] [Abstract][Full Text] [Related]
22. Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor.
Buck E; Bourne H; Wells JA
J Biol Chem; 2005 Feb; 280(6):4009-12. PubMed ID: 15550394
[TBL] [Abstract][Full Text] [Related]
23. Cloning and characterization of the guinea pig C5a anaphylatoxin receptor: interspecies diversity among the C5a receptors.
Fukuoka Y; Ember JA; Yasui A; Hugli TE
Int Immunol; 1998 Mar; 10(3):275-83. PubMed ID: 9576615
[TBL] [Abstract][Full Text] [Related]
24. Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor.
Buck E; Wells JA
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2719-24. PubMed ID: 15710877
[TBL] [Abstract][Full Text] [Related]
25. Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor.
Cain SA; Woodruff TM; Taylor SM; Fairlie DP; Sanderson SD; Monk PN
Biochem Pharmacol; 2001 Jun; 61(12):1571-9. PubMed ID: 11377387
[TBL] [Abstract][Full Text] [Related]
26. Allosterism in human complement component 5a ((h)C5a): a damper of C5a receptor (C5aR) signaling.
Rana S; Sahoo AR; Majhi BK
J Biomol Struct Dyn; 2016 Jun; 34(6):1201-13. PubMed ID: 26212097
[TBL] [Abstract][Full Text] [Related]
27. Function, structure and therapeutic potential of complement C5a receptors.
Monk PN; Scola AM; Madala P; Fairlie DP
Br J Pharmacol; 2007 Oct; 152(4):429-48. PubMed ID: 17603557
[TBL] [Abstract][Full Text] [Related]
28. Identification of the major phosphorylation sites in human C5a anaphylatoxin receptor in vivo.
Giannini E; Brouchon L; Boulay F
J Biol Chem; 1995 Aug; 270(32):19166-72. PubMed ID: 7642584
[TBL] [Abstract][Full Text] [Related]
29. C5aR ligand peptide 3D QSAR study performed with an applied linear conformation.
Anderson CY; Kellogg GE; Freer RJ
J Pept Res; 1997 Jun; 49(6):476-83. PubMed ID: 9266474
[TBL] [Abstract][Full Text] [Related]
30. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis.
Kola A; Baensch M; Bautsch W; Hennecke M; Klos A; Casaretto M; Köhl J
Immunotechnology; 1996 Jun; 2(2):115-26. PubMed ID: 9373320
[TBL] [Abstract][Full Text] [Related]
31. Evidence that the extracellular N-terminal domain of C5aR contains amino-acid residues crucial for C5a binding.
Mery L; Boulay F
Eur J Haematol; 1993 Nov; 51(5):282-7. PubMed ID: 8282089
[TBL] [Abstract][Full Text] [Related]
32. Complement component 5a receptor oligomerization and homologous receptor down-regulation.
Rabiet MJ; Huet E; Boulay F
J Biol Chem; 2008 Nov; 283(45):31038-46. PubMed ID: 18772131
[TBL] [Abstract][Full Text] [Related]
33. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
34. Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils.
Eglite S; Plüss K; Dahinden CA
J Immunol; 2000 Aug; 165(4):2183-9. PubMed ID: 10925305
[TBL] [Abstract][Full Text] [Related]
35. Antagonistic peptides against human anaphylatoxin C5a.
Kaneko Y; Okada N; Baranyi L; Azuma T; Okada H
Immunology; 1995 Sep; 86(1):149-54. PubMed ID: 7590876
[TBL] [Abstract][Full Text] [Related]
36. Characterization of rat C5a anaphylatoxin receptor (C5aR): cloning of rat C5aR cDNA and study of C5aR expression by rat astrocytes.
Sayah S; Patte C; Gasque P; Chan P; Ischenko A; Vaudry H; Fontaine M
Brain Res Mol Brain Res; 1997 Sep; 48(2):215-22. PubMed ID: 9332718
[TBL] [Abstract][Full Text] [Related]
37. The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding.
Scola AM; Higginbottom A; Partridge LJ; Reid RC; Woodruff T; Taylor SM; Fairlie DP; Monk PN
J Biol Chem; 2007 Feb; 282(6):3664-71. PubMed ID: 17158873
[TBL] [Abstract][Full Text] [Related]
38. Third extracellular loop (EC3)-N terminus interaction is important for seven-transmembrane domain receptor function: implications for an activation microswitch region.
Rana S; Baranski TJ
J Biol Chem; 2010 Oct; 285(41):31472-83. PubMed ID: 20663868
[TBL] [Abstract][Full Text] [Related]
39. Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain.
Oppermann M; Raedt U; Hebell T; Schmidt B; Zimmermann B; Götze O
J Immunol; 1993 Oct; 151(7):3785-94. PubMed ID: 8376805
[TBL] [Abstract][Full Text] [Related]
40. Mutation of glutamate 199 of the human C5a receptor defines a binding site for ligand distinct from the receptor N terminus.
Monk PN; Barker MD; Partridge LJ; Pease JE
J Biol Chem; 1995 Jul; 270(28):16625-9. PubMed ID: 7622471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
